Search

Researchers at AstraZeneca in Cambridge, United Kingdom, have conducted a study on the monoclonal antibody Anifrolumab, which targets the type I interferon receptor. The study utilized a physiology-based pharmacokinetic model and relative transcriptomics to evaluate tissue distribution and receptor occupancy of Anifrolumab. The results of the study informed dosing strategies for phase III trials of Anifrolumab in new indications and demonstrated a novel approach to modeling the pharmacokinetics of therapeutic monoclonal antibodies. [Extracted from the article]

A recent study conducted by investigators at AstraZeneca has found that tezepelumab, a medication used to treat severe, uncontrolled asthma, significantly reduces asthma exacerbations compared to a placebo. The study analyzed the efficacy of tezepelumab in various clinically relevant subgroups of patients and found that reductions in exacerbations were observed across a wide range of patient characteristics. The findings support the benefits of tezepelumab in patients with severe, uncontrolled asthma and can help inform healthcare providers' treatment decisions. The study was funded by AstraZeneca and has been peer-reviewed. [Extracted from the article]

A recent study conducted by AstraZeneca in Gaithersburg, Maryland, investigated the effects of benralizumab, a monoclonal antibody, on patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The study found that benralizumab led to a rapid and sustained depletion of eosinophils, a type of white blood cell, in both blood and nasal polyp tissue. The treatment also resulted in a reduction of inflammatory mediators in the nasal lining fluid. These findings suggest that benralizumab may be an effective therapy for CRSwNP. [Extracted from the article]

A recent study conducted by AstraZeneca in Gothenburg, Sweden, examined the use of tezepelumab, a monoclonal antibody, in patients with severe, uncontrolled asthma. The study found that a fixed-dose regimen of tezepelumab 210 mg every 4 weeks was suitable for eligible adults and adolescents with this condition. The research also determined that tezepelumab exposure was not significantly affected by factors such as age, sex, race/ethnicity, renal or hepatic function, disease severity, concomitant medication use, smoking history, or anti-drug antibodies. The study concluded that tezepelumab may be an effective treatment option for patients with severe, uncontrolled asthma. [Extracted from the article]

A new report presents fresh data on asthma, specifically focusing on patient adherence to biologic therapies. The study, conducted by researchers from AstraZeneca, aimed to describe real-world, specialist-reported biologic administration and adherence among US adults with severe asthma. The findings showed that most patients were adherent to biologic therapies, but adherence varied depending on the type of biologic and the method of administration. The research suggests that specialist-reported administration data provide a unique perspective on biologic adherence, which may differ from estimates based on insurance claims data. [Extracted from the article]

According to the news editors, the research concluded: "These differences can inform provider treatment decisions when selecting biologic treatments for patients with allergic severe asthma." A literature search was performed to identify published phase 3 RCT data of US Food and Drug Administration-approved biologics for severe asthma in patients with severe, uncontrolled asthma and confirmed sensitization to perennial aeroallergens. [Extracted from the article]

Keywords: Gaithersburg; State:Maryland; United States; North and Central America; AstraZeneca; Biological Factors; Business; CD Antigens; CD4 Antigens; CD8 Antigens; Cancer; Carcinomas; Drugs and Therapies; Health and Medicine; Immunologic Agents; Immunology; Interleukin-16 Receptors; Liver Cancer; Monoclonal Antibodies; Oncology; Pharmaceutical Companies; Pharmaceuticals; T-Lymphocyte Antigens; Tremelimumab Therapy EN Gaithersburg State:Maryland United States North and Central America AstraZeneca Biological Factors Business CD Antigens CD4 Antigens CD8 Antigens Cancer Carcinomas Drugs and Therapies Health and Medicine Immunologic Agents Immunology Interleukin-16 Receptors Liver Cancer Monoclonal Antibodies Oncology Pharmaceutical Companies Pharmaceuticals T-Lymphocyte Antigens Tremelimumab Therapy 480 480 1 09/11/23 20230914 NES 230914 2023 SEP 12 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on Oncology - Liver Cancer have been published. Keywords for this news article include: Gaithersburg, Maryland, United States, North and Central America, AstraZeneca, Biological Factors, Business, Business, CD Antigens, CD4 Antigens, CD8 Antigens, Cancer, Carcinomas, Drugs and Therapies, Health and Medicine, Immunologic Agents, Immunology, Interleukin-16 Receptors, Liver Cancer, Monoclonal Antibodies, Oncology, Pharmaceutical Companies, Pharmaceuticals, T-Lymphocyte Antigens, Tremelimumab Therapy, AstraZeneca. [Extracted from the article]

Keywords: Gaithersburg; State:Maryland; United States; North and Central America; AstraZeneca; Business; Cancer; Carcinomas; Drugs and Therapies; Durvalumab Therapy; Health and Medicine; Immunologic Agents; Immunotherapy; Liver Cancer; Monoclonal Antibodies; Oncology; Pharmaceutical Companies; Pharmaceuticals; Pharmacokinetics; Pharmacology; Tremelimumab Therapy EN Gaithersburg State:Maryland United States North and Central America AstraZeneca Business Cancer Carcinomas Drugs and Therapies Durvalumab Therapy Health and Medicine Immunologic Agents Immunotherapy Liver Cancer Monoclonal Antibodies Oncology Pharmaceutical Companies Pharmaceuticals Pharmacokinetics Pharmacology Tremelimumab Therapy 723 723 1 07/24/23 20230725 NES 230725 2023 JUL 25 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators discuss new findings in Oncology - Liver Cancer. For more information on this research see: Population Pharmacokinetics and Exposure-response Analysis of Tremelimumab 300 Mg Single Dose Combined With Durvalumab 1500 Mg Q4w (Stride) In Patients With Unresectable Hepatocellular Carcinoma. [Extracted from the article]